This document contains a detailed financial analysis of Valeant Pharmaceuticals (VRX) for the fiscal year 2016, Q3 2016, and projections for 2017 and 2018. It includes revenue, EBITDA, interest, taxes, capex, free cash flow, debt structure, and market data.
doj/DataSet10/EFTA01385389.pdf
{"title":"Valeant Pharmaceuticals Financial Data","document_date":"January 2018","document_type":"tabular","key_organizations":["Valeant Pharmaceuticals","Deutsche Bank Securities Inc."],"reference_numbers":["DB-SDNY-0086673","SDNY_GM_00232857","EFTA01385389"]}